Cited 29 times in
Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신재일 | - |
dc.contributor.author | 이금화 | - |
dc.date.accessioned | 2021-09-29T01:38:18Z | - |
dc.date.available | 2021-09-29T01:38:18Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1128-3602 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184472 | - |
dc.description.abstract | Objective: We aimed to analyze clinical characteristics, treatment patterns, and prognosis of patients with reversible cerebral vasoconstriction syndrome (RCVS). Materials and methods: Two investigators independently searched PubMed and EMBASE, and 191 cases were included in this study. Information regarding demographics, triggering factors, brain imaging findings, treatment modalities, recurrence, and clinical outcome was collected. Results: The mean age of the patients was 39.9 years, and 155 (81.2%) were female. The most common triggering factor for RCVS was an exposure to vasoactive substances (41.4%), followed by pregnancy/postpartum (20.9%), and sexual intercourse (10.5%). Multifocal stenosis (84.0%) and beading shape (82.4%) were the leading abnormal findings on angiography, while cerebral ischemic lesions (47.6%) and cerebral hemorrhage (mainly subarachnoid hemorrhage) (35.1%) were the main findings on brain computed tomography (CT)/magnetic resonance imaging (MRI). Calcium channel blockers (nimodipine/verapamil) were the most commonly used medications (44.5%) in the treatment of RCVS. Multivariate analysis identified that RCVS was precipitated by trauma/surgery/procedure (hazard ratio (HR): 3.29, 95% confidence interval (CI) (1.21-8.88), p=0.019), and presence of aphasia/neglect/apraxia during the acute phase of the disease (HR: 3.83, 95% CI (1.33-11.05), p=0.013) were found to be the two independent risk factors for residual neurological deficit after RCVS. Conclusions: In our systematic review, vasoactive substances were the most frequent triggers for RCVS, which was most commonly accompanied by angiographic findings of multifocal stenotic lesions. Patients with RCVS precipitated by trauma or surgical procedures and those with focal cortical deficits had a higher risk of residual neurological deficits, and these patients should closely be monitored. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Verduci | - |
dc.relation.isPartOf | EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | T-J Song | - |
dc.contributor.googleauthor | K H Lee | - |
dc.contributor.googleauthor | H Li | - |
dc.contributor.googleauthor | J Y Kim | - |
dc.contributor.googleauthor | K Chang | - |
dc.contributor.googleauthor | S H Kim | - |
dc.contributor.googleauthor | K H Han | - |
dc.contributor.googleauthor | B Y Kim | - |
dc.contributor.googleauthor | A Kronbichler | - |
dc.contributor.googleauthor | A Ducros | - |
dc.contributor.googleauthor | A Koyanagi | - |
dc.contributor.googleauthor | L Jacob | - |
dc.contributor.googleauthor | M S Kim | - |
dc.contributor.googleauthor | D K Yon | - |
dc.contributor.googleauthor | S W Lee | - |
dc.contributor.googleauthor | J M Yang | - |
dc.contributor.googleauthor | S H Hong | - |
dc.contributor.googleauthor | R A Ghayda | - |
dc.contributor.googleauthor | J W Kang | - |
dc.contributor.googleauthor | J I Shin | - |
dc.contributor.googleauthor | L Smith | - |
dc.identifier.doi | 10.26355/eurrev_202105_25834 | - |
dc.contributor.localId | A02142 | - |
dc.contributor.localId | A04622 | - |
dc.relation.journalcode | J03872 | - |
dc.identifier.eissn | 2284-0729 | - |
dc.identifier.pmid | 34002826 | - |
dc.contributor.alternativeName | Shin, Jae Il | - |
dc.contributor.affiliatedAuthor | 신재일 | - |
dc.contributor.affiliatedAuthor | 이금화 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 3519 | - |
dc.citation.endPage | 3529 | - |
dc.identifier.bibliographicCitation | EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, Vol.25(9) : 3519-3529, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.